2020 US Microbiology Lab and POC Market for 100 Tests: Supplier Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers
LeadingMarketResearch.com presents a new strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Opportunities and Strategic Recommendations
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Market Segmentation Analysis
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Contains 1,037 pages and 177 tables
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Opportunities and Strategic Recommendations
- Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Market Segmentation Analysis
- Sales and market shares of major suppliers by individual test.
- Volume and sales forecasts for over 100 infectious disease assays by individual test and market segment:
- Hospitals
- Blood Banks
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Public Health Laboratories
- Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).
- Review of the market dynamics, trends, structure, size, growth and major suppliers.
- In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.
- Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.
- Global listings of companies developing or marketing infectious disease diagnostic products by individual test.
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Contains 1,037 pages and 177 tables
More Publications
2017-2021 US Nucleic Acid Testing/NAT Market: Growth Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
US$ 8,550.00
February 2017
1157 pages
The US Infectious Disease Testing Market 2015: Sales Forecasts by Market Segment and Supplier Shares by Test
US$ 680.00
May 2015
43 pages
2016-2020 US Immunodiagnostics Market: Instrument and Reagent Supplier Shares, and Test Category Sales Forecasts
US$ 760.00
March 2016
35 pages
2015-2019 Future Horizons and Growth Strategies in the US Hemostasis Diagnostic Testing Market: Supplier Shares and Country Forecasts
US$ 7,680.00
September 2015
424 pages
US Hospital Hemostasis Testing Market: Forecasts for 40 Coagulation Assays, Supplier Shares, 2019-2023
US$ 3,850.00
July 2019
411 pages
